Brokerages expect SAGE Therapeutics Inc (NASDAQ:SAGE) to announce ($3.32) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for SAGE Therapeutics’ earnings, with the lowest EPS estimate coming in at ($3.63) and the highest estimate coming in at ($2.89). SAGE Therapeutics reported earnings of ($0.36) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 822.2%. The business is expected to issue its next earnings results on Tuesday, August 6th.
On average, analysts expect that SAGE Therapeutics will report full year earnings of ($13.19) per share for the current financial year, with EPS estimates ranging from ($14.54) to ($11.34). For the next year, analysts anticipate that the firm will post earnings of ($11.76) per share, with EPS estimates ranging from ($16.21) to ($8.85). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow SAGE Therapeutics.
SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($3.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($3.17) by ($0.20). The business had revenue of $0.47 million during the quarter. During the same period last year, the business posted ($1.68) EPS.
Shares of SAGE opened at $169.60 on Friday. SAGE Therapeutics has a 52-week low of $79.88 and a 52-week high of $178.16. The company has a market capitalization of $8.99 billion, a price-to-earnings ratio of -20.99 and a beta of 2.66. The company has a current ratio of 20.06, a quick ratio of 20.06 and a debt-to-equity ratio of 0.03.
In related news, Director Steven M. Paul sold 60,421 shares of SAGE Therapeutics stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $161.28, for a total value of $9,744,698.88. Following the sale, the director now owns 272,777 shares of the company’s stock, valued at approximately $43,993,474.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven M. Paul sold 3,775 shares of SAGE Therapeutics stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $161.05, for a total transaction of $607,963.75. Following the completion of the sale, the director now directly owns 272,777 shares in the company, valued at approximately $43,930,735.85. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 291,121 shares of company stock valued at $49,791,439. 4.60% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. M&R Capital Management Inc. purchased a new position in SAGE Therapeutics during the fourth quarter worth about $28,000. Benjamin F. Edwards & Company Inc. purchased a new position in shares of SAGE Therapeutics during the fourth quarter worth approximately $29,000. Daiwa Securities Group Inc. grew its position in shares of SAGE Therapeutics by 34.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 310 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 80 shares during the last quarter. Icon Wealth Partners LLC purchased a new position in shares of SAGE Therapeutics during the first quarter worth approximately $31,000. Finally, Mckinley Capital Management LLC Delaware grew its position in shares of SAGE Therapeutics by 53.3% during the first quarter. Mckinley Capital Management LLC Delaware now owns 282 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 98 shares during the last quarter.
About SAGE Therapeutics
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Further Reading: How is the LIBOR rate calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.